Cargando…

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective. Methods: A s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Zhe, Chen, Qi, Wei, Ruiqi, Ma, Chenyao, Zhang, Xuehui, Chen, Xue, Fang, Fang, Zhao, Quanming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080443/ https://www.ncbi.nlm.nih.gov/pubmed/33935749 http://dx.doi.org/10.3389/fphar.2021.648244

Ejemplares similares

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway
por: Liu, Jing, et al.
Publicado: (2021)

Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Min, et al.
Publicado: (2018)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease
por: Paolisso, Pasquale, et al.
Publicado: (2020)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction
por: Trompet, Stella, et al.
Publicado: (2022)

Addition of Plasma Myeloperoxidase and Trimethylamine N-Oxide to the GRACE Score Improves Prediction of Near-Term Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction
por: Tan, Yu, et al.
Publicado: (2021)

Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction
por: Campain, Anna, et al.
Publicado: (2022)

Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention
por: Yin, Xiaoying, et al.
Publicado: (2023)

The Role of Autophagy in Acute Myocardial Infarction
por: Wu, Du, et al.
Publicado: (2019)

Intervention effects of traditional Chinese medicine on stem cell therapy of myocardial infarction
por: Wang, Yu, et al.
Publicado: (2022)

Multipronged Therapeutic Effects of Chinese Herbal Medicine Qishenyiqi in the Treatment of Acute Myocardial Infarction
por: Wang, Yong, et al.
Publicado: (2017)

Cathepsin S degrades arresten and canstatin in infarcted area after myocardial infarction in rats
por: SUGIYAMA, Akira, et al.
Publicado: (2019)

(Re) Solving Repair After Myocardial Infarction
por: Leoni, Giovanna, et al.
Publicado: (2018)

Resveratrol Attenuate Myocardial Injury by Inhibiting Ferroptosis Via Inducing KAT5/GPX4 in Myocardial Infarction
por: Liu, Jing, et al.
Publicado: (2022)

Predictive value of myocardial strain on myocardial infarction size by cardiac magnetic resonance imaging in ST-segment elevation myocardial infarction with preserved left ventricular ejection fraction
por: Wang, Qiang, et al.
Publicado: (2022)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

Circadian Dependence of the Acute Immune Response to Myocardial Infarction
por: Kilgallen, Aoife B., et al.
Publicado: (2022)

The Effect of Chinese Medicine on Lipid and Glucose Metabolism in Acute Myocardial Infarction Through PPARγ Pathway
por: Zhang, Qian, et al.
Publicado: (2018)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
por: Wang, Hong-Fei, et al.
Publicado: (2022)

Comparative Pharmacokinetics of Gallic Acid After Oral Administration of Gallic Acid Monohydrate in Normal and Isoproterenol-Induced Myocardial Infarcted Rats
por: Yu, Zhe, et al.
Publicado: (2018)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
por: Zheng, Meifan, et al.
Publicado: (2020)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
por: Hagström, Emil, et al.
Publicado: (2022)

The circRNA-miRNA/RBP regulatory network in myocardial infarction
por: Zhang, Lei, et al.
Publicado: (2022)

The association between plasma furin and cardiovascular events after acute myocardial infarction
por: Liu, Zhi-Wei, et al.
Publicado: (2021)

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases
por: Chen, Jianqiao, et al.
Publicado: (2022)

Montelukast Use Decreases Cardiovascular Events in Asthmatics
por: Hoxha, Malvina, et al.
Publicado: (2021)

Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review
por: Chen, Yingying, et al.
Publicado: (2023)

Basic Fibroblast Growth Factor Attenuates Injury in Myocardial Infarction by Enhancing Hypoxia-Inducible Factor-1 Alpha Accumulation
por: Rao, Zhiheng, et al.
Publicado: (2020)

Metformin Protects the Heart Against Hypertrophic and Apoptotic Remodeling After Myocardial Infarction
por: Loi, Halyna, et al.
Publicado: (2019)

The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction
por: Di Martino, Mirko, et al.
Publicado: (2015)

Activation of the sirtuin silent information regulator 1 pathway inhibits pathological myocardial remodeling
por: Wang, Youheng, et al.
Publicado: (2023)

RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017)

Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019)

Identification of the biological processes, immune cell landscape, and hub genes shared by acute anaphylaxis and ST-segment elevation myocardial infarction
por: Peng, Zekun, et al.
Publicado: (2023)

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v86956hjndta7hcktribp6o0fs